Delgado Sigfrido 4

What Happened
Sigfrido Delgado, Senior VP of Operations at Avanos Medical (AVNS), was granted a total of 53,406 equity awards on March 13, 2026: 15,886 time‑based restricted share units (TRSUs) and 37,520 derivative awards reported as TRSU‑equivalents. Both grants were reported at $0 per unit (no cash purchase); each TRSU is the economic equivalent of one share of common stock. These awards are compensation grants, not open‑market purchases or sales.

Key Details

• Transaction date: March 13, 2026; Form 4 filed March 17, 2026 (timely — within the SEC’s two business‑day requirement).
• Grant amounts and pricing: 15,886 TRSUs @ $0.00 (F1); 37,520 units reported as derivative TRSUs @ $0.00 (F2). Total = 53,406 units.
• Vesting schedules: F1 award vests 1/3 on 3/13/2027, 1/3 on 3/13/2028, 1/3 on 3/13/2029. F2 award vests 30% on 3/13/2027, 30% on 3/13/2028, 40% on 3/13/2029.
• Shares owned after transaction: not specified in the filing.
• Footnotes: F1 = time‑based restricted share units under the 2021 LTIP; F2 = specifies the 30/30/40 vesting split. No 10b5‑1, tax‑withholding, or sale information was reported.

Context
These are compensation awards that will convert to economic exposure to Avanos common stock only as they vest; they do not represent an immediate purchase or sale. Such grants are routine for executive compensation and should be viewed as part of long‑term retention/incentive programs rather than an immediate market sentiment signal.